Bio-Techne Corporation (TECH)

Market Cap	9.99B -16.3%
Revenue (ttm)	1.22B +3.9%
Net Income	77.95M -48.3%
EPS	0.49 -48.7%
Shares Out	155.81M
PE Ratio	131.67
Forward PE	31.74
Dividend	$0.32 (0.50%)
Ex-Dividend Date	Nov 17, 2025

Volume	2,485,744
Open	63.26
Previous Close	63.98
Day's Range	62.81 - 64.35
52-Week Range	46.01 - 79.28
Beta	1.47
Analysts	Buy
Price Target	70.46 (+9.94%)
Earnings Date	Feb 4, 2026

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue cultur...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,100
• Stock Exchange: NASDAQ
• Ticker Symbol: TECH
• Website: https://www.bio-techne.com

Financial Performance

In fiscal year 2025, Bio-Techne's revenue was $1.22 billion, an increase of 5.23% compared to the previous year's $1.16 billion. Earnings were $73.36 million, a decrease of -56.35%.

Analyst Summary

According to 14 analysts, the average rating for TECH stock is "Buy." The 12-month stock price target is $70.46, which is an increase of 9.94% from the latest price.

Price Target

$70.46

(9.94% upside)

Analyst Consensus: Buy